{
    "nct_id": "NCT04754321",
    "official_title": "HNSALV Trial: Combining Immunotherapy with Salvage Surgery and IORT for Treatment of Persistent/Recurrent Head and Neck Cancers",
    "inclusion_criteria": "* Pathologically confirmed either persistent and/ or locoregionally recurrent HNSCC of oral cavity, pharynx, larynx, unknown primary head and neck (H&N) squamous cell carcinoma\n* Resectable disease as determined by the surgeon and team\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) < 2\n* At least 18 years of age\n* Adequate hematologic, renal, and hepatic function\n* Must have at least 2 week washout period from prior therapy\n* Willingness and ability to provide informed consent\n* Negative pregnancy test for females of reproductive potential\n* Patients who have undergone therapy for their cancer, such as surgery and/or chemotherapy and/or radiotherapy and recurred\n* Disease measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria.\n* Prior definitive and palliative chemotherapy will be allowed\n* Prior radiation therapy will be allowed\n* Tumor tissue from resected site of disease must be provided for biomarker analyses, in addition to urine and blood sample as scheduled per protocol\n* White blood cell (WBC) >= 2000/uL (obtained within 14 days of randomization)\n* Neutrophils >= 1500/uL (obtained within 14 days of randomization)\n* Platelets >= 100 x10^3/uL (obtained within 14 days of randomization)\n* Hemoglobin > 9.0 g/dL (obtained within 14 days of randomization)\n* Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance (CrCl) >= 40 mL/min (Cockcroft and Gault or Wright formula may be used according to local practice) (obtained within 14 days of randomization)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional ULN\n* Total Bilirubin =< 1.5 x institutional ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)\n* Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for four months after the last dose of pembrolizumab.\n* Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG])\n* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of four months after the last dose of investigational product\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Requirement of immunosuppressive therapy within 14 days of randomization\n* Salivary gland carcinomas, lip carcinoma, adenocarcinoma of the skin\n* Prior use of immune checkpoint blockade agent\n* History of human immunodeficiency virus (HIV), hepatitis B, C: Participants who test positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection, those who test positive for human immunodeficiency virus (HIV) or have known acquired immunodeficiency syndrome (AIDS)\n* Unresectable disease, as determined by the surgeon and team\n* Subjects with history of grade 3 toxicity with prior immunotherapy\n* Patients with distant metastases\n* Subjects with active autoimmune disease\n* Breastfeeding women\n* Additional prior malignancy within the previous 3 years (treated or untreated, except for skin carcinomas treated with excision alone and carcinoma in situ of the cervix)\n* Palliative radiotherapy less than 14 days prior to first dose of study drug\n* Any history of hypersensitivity to any of the trial medications\n* Poorly controlled or serious medical or psychiatric illness likely to interfere with participation and/or compliance in this clinical trial\n* Prisoners or subjects who are involuntarily incarcerated\n* Patients not available for follow-up/future contact as defined in the ICF\n* Note: Patients on this protocol are not excluded from participation in other clinical trials",
    "miscellaneous_criteria": ""
}